IN THE CLAIMS

**COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS**
(Currently amended claims showing deletions by ~~strikethrough~~ and additions by underlining)

This listing of claims will replace all prior versions and listings of the claims in the application.

Listing of Claims:

1. (previously presented) A compound, or prodrug, tautomeric, pharmaceutically acceptable salt, or stereoisomeric form thereof, having a structure of Formula II:




wherein

B represents $M_nR_8$;

Ar represents an aryl or heteroaryl ring;

V represents O, S, or N-CN;

W represents O, S, or NR'';

R' represents, independently for each occurrence, H, lower alkyl, or a metal counterion;

R'' represents, independently for each occurrence, H or lower alkyl;

$R_5$ represents H, $P(=O)(OR')_2$, or $M_nQ$;

$R_6$ represents H, OH, or $M_nQ$, provided that only one of $R_5$ and $R_6$ represents H;

$R_7$ represents H, halogen, hydroxyl, lower alkyl or lower alkoxyl;

$R_8$ represents substituted or unsubstituted alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, cycloalkyl, heterocyclyl, or amine;

M, independently for each occurrence, represents a substituted or unsubstituted methylene group (including C(=O) and C(=S)), NR'', O, S, S(O), or $S(O_2)$;

n represents an integer from 1-4 when present in B, from 0-6 when present in $R_5$, and from 1-3 when present in $R_6$; and

Q represents a substituted or unsubstituted: tertiary amino substituent, or nitrogen-containing heterocycle.

2. (original) A compound of claim 1, wherein $R_8$ represents substituted or unsubstituted morpholino, piperazinyl, or cyclohexyl.

3. (original) A compound of claim 1, wherein R" represents H.

4. (original) A compound of claim 1, wherein $R_5$ represents $M_nQ$.

5. (original) A compound of claim 4, wherein the occurrence of M attached to Q represents $CH_2$, $S(O_2)$, C(=S), or C(=O).

6. (original) A compound of claim 5, wherein the occurrence of M attached to Q represents $CH_2$.

7. (original) A compound of claim 5, wherein the occurrence of M attached to Q is C(=O).

8. (original) A compound of claim 4, wherein the occurrence of M attached to Q represents substituted NR''.

9. (original) A compound of claim 4, wherein Q represents a substituted or unsubstituted nitrogen-containing heterocycle.

10. (original) A compound of claim 4, wherein Q represents a substituted or unsubstituted tertiary amino group.

11. (previously presented) A compound, or a prodrug, tautomeric, pharmaceutically acceptable salt, or stereoisomeric form thereof, having a structure of Formula II:



wherein

B represents $M_nR_8$;

Ar represents an aryl or heteroaryl ring;

V represents O, S, or N-CN;

W represents O, S, or NR'';

R' represents, independently for each occurrence, H, lower alkyl, or a metal counterion;

R'' represents, independently for each occurrence, H or lower alkyl;

R''' represents H or optionally substituted lower alkyl;

$R_5$ represents $M_nJK$;

$R_6$ represents H, OH, or $M_nQ$;

$R_7$ represents H, halogen, hydroxyl, lower alkyl or lower alkoxyl;

$R_8$ represents substituted or unsubstituted alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, cycloalkyl, heterocyclyl, or amine;

J represents C(=O), C(=S), or $SO_2$;

K represents OR', $N(R'')_2$, or $N(R')SO_2R''$;

M, independently for each occurrence, represents a substituted or unsubstituted methylene group, NR'', O, S, S(O), or $S(O_2)$;

n represents an integer from 1-7 when present in B, from 0-6 when present in $R_5$, and from 1-3 when present in $R_6$; and

Q represents a substituted or unsubstituted: tertiary amino substituent or nitrogen-containing heterocycle.

12. (original) A compound of claim 11, wherein $R_8$ represents substituted or unsubstituted morpholino, piperazinyl, or cyclohexyl.

13. (original) A compound of claim 11, wherein R" represents H.

14. (original) A compound of claim 11, wherein $R_6$ represents $M_nQ$.

15. (original) A compound of claim 14, wherein the occurrence of M attached to Q represents $CH_2$, $S(O_2)$, C(=S), or C(=O).

16. (original) A compound of claim 15, wherein the occurrence of M attached to Q is C(=O).

17. (original) A compound of claim 15, wherein the occurrence of M attached to Q represents $CH_2$.

18. (original) A compound of claim 14, wherein the occurrence of M attached to Q represents substituted NR''.

19. (original) A compound of claim 14, wherein Q represents a substituted or unsubstituted tertiary amino substituent.

20. (original) A compound of claim 14, wherein Q represents a substituted or unsubstituted nitrogen-containing heterocycle.

21. (original) A compound of any of claims 1, 7, 9 and 11, wherein substituents include, independently for each occurrence, alkyl, oxo, acyl amino, hydroxyl, carbonyl, sulfonyl, ester, amide, NR", hydroxy alkyl, alkoxy alkyl, aryl, heterocyclyl, cycloalkyl, or oligo(ethylene glycol).

22. (original) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of any of claims 1, 7, 9 and 11.

23. (currently amended) A method of ~~treating a~~ inhibiting the growth of a cyclin dependent kinase (CDK)-dependent or CDK-inhibitor responsive hyperproliferative disease (tumor) ~~hyperproliferative disorder~~, comprising administering to an animal a compound of any one of claims 1, 7, 9 and 11.

24. (currently amended) A method of inhibiting proliferation of a cell, comprising contacting the cell with a compound of any one of claims 1, 7, 9 and 11.

25. (cancelled)

26. (currently amended) A method of treating a viral infection, comprising administering to a mammal a compound of any one of claims 1, 7, 9, and 11, ~~The method of claim 25,~~ wherein the viral infection is caused by a virus selected from the group consisting of a human immunodeficiency virus (HIV), human papilloma virus, herpesvirus, poxvirus, Epstein-Barr virus, Sindbis virus, and adenovirus.

27. (currently amended) A method for the treatment or prevention of alopecia induced by chemotherapy or radiation therapy, comprising administering to a mammal a compound of any one of claims 1, 7, 9, and 11 conjointly with one or more chemotherapeutics or radiation therapy.

28-41. (cancelled)

42. (new) The method of Claim 23, wherein said CDK-inhibitor responsive hyperproliferative disease is selected from the group consisting of cancer, benign prostate hyperplasia, familial adenomatosis polyposis, neurofibromatosis, psoriasis, fungal infections, endotoxic shock, hypertrophic scar formation, inflammatory bowel disease, transplant rejection, vascular smooth muscle cell proliferation associated with atherosclerosis, psoriasis, pulmonary fibrosis, arthritis, glomerulonephritis, restenosis following angioplasty or vascular surgery, and other post-surgical stenosis and restenosis.

43. (new) The method of Claim 43, wherein said CDK-inhibitor responsive hyperproliferative disease is a cancer selected from the group consisting of carcinoma, including that of the bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, esophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage, including leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma, and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplastic syndrome, and promyelocytic leukemia; tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; tumors of the central and peripheral nervous system, including astrocytoma, neuroblastoma, glioma, and schwannomas; and other tumors, including melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer, and Kaposi's sarcoma.